An open-label phase II study of dostarlimab (TSR-042), bevacizumab (bev), and niraparib combination in patients (pts) with platinum-resistant ovarian cancer (PROC): cohort A of the OPAL trial
暂无分享,去创建一个
Ping Wang | E. Ratner | G. Konecny | R. Arend | Joyce F. Liu | C. Gunderson | J. Moroney | L. Evilevitch | S. Gaillard | A. W. Hendrickson | D. Gupta | O. Yeku | E. Diver | V. Samnotra | Xiaohong Liu | Jo-Hsin Tang | Sarah Wang | E. Bacque